Synapse - Works

Results (115781)

Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R(2)) for first-line treatment of follicular lymphoma: Initial results from phase 1/2 trial

Meeting Abstract

Falchi, L.; Leslie, L. A.; Belada, D.; Kopeckova, K.; Offner, F.; Brody, J.; Canales, M.; García-Sancho, A. M.; Nijland, M.; Andersson, P. O.; more...
Blood (2022)

Fulltext@MSK | Save

Age, albumin, and LDH predict outcome of patients with limited stage peripheral T cell lymphoma: A prognostic model developed on 244 cases enrolled in the T cell project 1 by the International T Cell Project Network

Meeting Abstract

Hapgood, G.; Civallero, M.; Stepanishyna, Y.; Vose, J. M.; Cabrera, M. E.; Advani, R. H.; Pileri, S. A.; Manni, M.; Horwitz, S. M.; Foss, F. M.; more...
Blood (2022)

Fulltext@MSK | Save

CNS relapse in T-cell lymphoma index: A risk score to predict central nervous system relapse in patients with T-cell lymphomas

Meeting Abstract

Bhansali, R. S.; Ellin, F.; Cao, M.; Relander, T.; Li, W.; Long, Q.; Ganesan, N.; Stuver, R.; Horwitz, S. M.; Wudhikarn, K.; more...
Blood (2022)

Fulltext@MSK | Save

Predictors of long-term outcome in TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplant after first- or second-line therapy: Results from the consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Meeting Abstract

Badar, T.; Atallah, E. L.; Shallis, R. M.; Saliba, A. N.; Stahl, M. F.; Bewersdorf, J. P.; Grenet, J.; Patel, A. A.; Abaza, Y.; Murthy, G. S. G.; more...
Blood (2022)

Fulltext@MSK | Save

Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update

Meeting Abstract

Falchi, L.; Abrisqueta, P.; Nijland, M.; Leppä, S.; Hutchings, M.; Holte, H.; Merryman, R. W.; Lugtenburg, P.; de Vos, S.; Cheah, C. Y.; more...
Blood (2022)

Fulltext@MSK | Save

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study

Meeting Abstract

Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
Blood (2022)

Fulltext@MSK | Save

Predictive value of minimal residual disease on efficacy of rituximab maintenance in mantle cell lymphoma: Results from the European MCL Elderly trial

Meeting Abstract

Hoster, E.; Delfau, M. H.; Macintyre, E. A.; Jiang, L. M.; Stilgenbauer, S.; Vehling-Kaiser, U.; Salles, G.; Thieblemont, C.; Tilly, H.; Kanz, L.; more...
Blood (2022)

Fulltext@MSK | Save

A genome-wide association study (GWAS) of event-free survival (EFS) in follicular lymphoma patients treated with front-line immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

Meeting Abstract

Ghesquieres, H.; Drouet, Y.; Slager, S. L.; Morschhauser, F.; Galimberti, S.; Robinson, D. P.; Thomas, E.; Novak, A. J.; Xerri, L.; Luminari, S.; more...
Blood (2022)

Fulltext@MSK | Save

Initial treatment response is prognostic and predictive of relapse patterns: Outcomes of >500 patients treated for primary CNS lymphoma

Meeting Abstract

Tringale, K. R.; Yahalom, J.; Scordo, M.; Cederquist, G. Y.; Vachha, B.; Schaff, L.; Hajj, C.; Hubbeling, H.; Zhang, Z.; White, C.; more...
Blood (2022)

Fulltext@MSK | Save

Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) NEX T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Costa, L. J.; Kumar, S. K.; Atrash, S.; Liedtke, M.; Kaur, G.; Derman, B. A.; Bergsagel, P. L.; Mailankody, S.; McCarthy, P. L.; Limones, J.; more...
Blood (2022)

Fulltext@MSK | Save